Previous close | 0.0226 |
Open | 0.0237 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 0.0226 - 0.0226 |
52-week range | 0.0100 - 0.1180 |
Volume | |
Avg. volume | 11,011 |
Market cap | 1.335M |
Beta (5Y monthly) | 1.89 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1690 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fellow Shareholders As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a broad-based and sharper-than-expected slowdown, increased inflation higher than we have seen in seve
AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in the clinicGenetic test kit evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy MIAMI, June 01, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will begin using precision med